GlaxoSmithKline Plc (GSK)-Financial and Strategic SWOT Analysis Review

GlaxoSmithKline Plc (GSK)-Financial and Strategic SWOT Analysis Review


  • Products Id :- GDPH4279FSA
  • |
  • Pages: 104
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

GlaxoSmithKline Plc (GSK)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description-A detailed description of the company's operations and business divisions.

Corporate strategy-Analyst's summarization of the company's business strategy.

SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history-Progression of key events associated with the company.

Major products and services-A list of major products, services and brands of the company.

Key competitors-A list of key competitors to the company.

Key employees-A list of the key executives of the company.

Executive biographies-A brief summary of the executives' employment history.

Key operational heads-A list of personnel heading key departments/functions.

Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities-A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

GlaxoSmithKline Plc (GSK) is a healthcare company, which focuses on the development, manufacture and commercialization of pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of respiratory, cancer, cardiovascular, HIV and infectious diseases, respiratory, immuno-inflammation and rare diseases. The company offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and respiratory diseases. GSK's vaccine portfolio cover various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups. GSK is headquartered in Brentford, Middlesex, the UK.

GlaxoSmithKline Plc Key Recent Developments

Apr 26,2017: GSK delivers another quarter of continued progress

Mar 22,2017: U.K. Biobank, Regeneron and GSK Announce Largest Gene Sequencing Initiative on World's Most Detailed Health Database to Improve Drug Discovery and Disease Diagnosis

Feb 16,2017: GSK and EMBL have signed an agreement to enhance understanding of disease and drug mechanisms

Feb 08,2017: GlaxoSmithKline: Results announcement for the fourth quarter 2016

Jan 19,2017: Abbas Hussain to leave GSK

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

GlaxoSmithKline Plc-Key Facts 6

GlaxoSmithKline Plc-Key Employees 7

GlaxoSmithKline Plc-Key Employee Biographies 8

GlaxoSmithKline Plc-Major Products and Services 9

GlaxoSmithKline Plc-Pharmaceutical Pipeline Products Data 10

GlaxoSmithKline Plc, Pipeline Products by Therapy Area 10

GlaxoSmithKline Plc, Pipeline Products by Development Phase 12

GlaxoSmithKline Plc-History 13

GlaxoSmithKline Plc-Company Statement 34

GlaxoSmithKline Plc-Locations And Subsidiaries 36

Head Office 36

Other Locations & Subsidiaries 36

Joint Venture 48

Section 2-Company Analysis 50

GlaxoSmithKline Plc-Business Description 50

GlaxoSmithKline Plc-Corporate Strategy 51

GlaxoSmithKline Plc-SWOT Analysis 52

SWOT Analysis-Overview 52

GlaxoSmithKline Plc-Strengths 52

GlaxoSmithKline Plc-Weaknesses 53

GlaxoSmithKline Plc-Opportunities 54

GlaxoSmithKline Plc-Threats 55

GlaxoSmithKline Plc-Key Competitors 56

Section 3-Company Financial Ratios 57

Financial Ratios-Capital Market Ratios 57

Financial Ratios-Annual Ratios 58

Performance Chart 61

Financial Performance 61

Financial Ratios-Interim Ratios 62

Financial Ratios-Ratio Charts 63

Section 4-Company's Lifesciences, Power Financial Deals and Alliances 64

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 64

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 65

GlaxoSmithKline Plc, Recent Deals Summary 66

Section 5-Company's Recent Developments 67

Apr 26, 2017: GSK delivers another quarter of continued progress 67

Mar 22, 2017: U.K. Biobank, Regeneron and GSK Announce Largest Gene Sequencing Initiative on World's Most Detailed Health Database to Improve Drug Discovery and Disease Diagnosis 70

Feb 16, 2017: GSK and EMBL have signed an agreement to enhance understanding of disease and drug mechanisms 72

Feb 08, 2017: GlaxoSmithKline: Results announcement for the fourth quarter 2016 73

Jan 19, 2017: Abbas Hussain to leave GSK 89

Jan 19, 2017: Luke Miels appointed President, Global Pharmaceuticals, GSK 90

Dec 19, 2016: GSK announces Board changes 91

Oct 26, 2016: GlaxoSmithKline: Results Announcement for the third quarter 2016 92

Oct 06, 2016: CRT and University of Manchester receive success payment from GlaxoSmithKline for cancer epigenetics research collaboration 98

Sep 29, 2016: GlaxoSmithKline appoints Brian McNamara as CEO of GSK Consumer Healthcare 99

Section 6-Appendix 100

Methodology 100

Ratio Definitions 100

About GlobalData 104

Contact Us 104

Disclaimer 104

List of Figures

GlaxoSmithKline Plc, Pipeline Products by Therapy Area 10

GlaxoSmithKline Plc, Pipeline Products by Development Phase 12

GlaxoSmithKline Plc, Performance Chart (2012-2016) 61

GlaxoSmithKline Plc, Ratio Charts 63

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 64

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 65

List of Tables

GlaxoSmithKline Plc, Key Facts 6

GlaxoSmithKline Plc, Key Employees 7

GlaxoSmithKline Plc, Key Employee Biographies 8

GlaxoSmithKline Plc, Major Products and Services 9

GlaxoSmithKline Plc, Number of Pipeline Products by Therapy Area 10

GlaxoSmithKline Plc, Number of Pipeline Products by Therapy Area (Cont...1) 11

GlaxoSmithKline Plc, Number of Pipeline Products by Development Stage 12

GlaxoSmithKline Plc, History 13

GlaxoSmithKline Plc, Other Locations 36

GlaxoSmithKline Plc, Subsidiaries 36

GlaxoSmithKline Plc, Joint Venture 48

GlaxoSmithKline Plc, Key Competitors 56

GlaxoSmithKline Plc, Ratios based on current share price 57

GlaxoSmithKline Plc, Annual Ratios 58

GlaxoSmithKline Plc, Annual Ratios (Cont...1) 59

GlaxoSmithKline Plc, Annual Ratios (Cont...2) 60

GlaxoSmithKline Plc, Interim Ratios 62

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 64

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 65

GlaxoSmithKline Plc, Recent Deals Summary 66

Currency Codes 100

Capital Market Ratios 100

Equity Ratios 101

Profitability Ratios 101

Cost Ratios 102

Liquidity Ratios 102

Leverage Ratios 103

Efficiency Ratios 103

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Sophiris Bio Inc, Sanofi, Pfizer Inc, Oragenics Inc, Novartis AG, NewLink Genetics Corp, Napp Pharmaceuticals Ltd, Merck & Co Inc, F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Cascadian Therapeutics Inc, Cardiome Pharma Corp, Bristol-Myers Squibb Company, Biofarm SA, AstraZeneca Plc, Aquinox Pharmaceuticals Inc, Amgen Inc

select a license
Single User License
USD 125 INR 8928
Site License
USD 250 INR 17855
Corporate User License
USD 375 INR 26783

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com